Sign in Create account

Welcure Drugs & Pharmaceuticals ltd

Healthcare · Pharmaceuticals & Biotechnology

BSE: 524661
₹0.21
▲ 0.00 (0.00%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
70/100
Strong
Valuation
100/100
Undervalued
Momentum
46/100
Neutral

QVM read Quality at a discount Quality Strong, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
Data unavailable.
PE (TTM)
0.1
Industry median 36.1 (152 companies)
Price to Book
Data unavailable.
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
0.00%
FII + DII, latest filed period
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-98.5
Free Cash Flow
₹2 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-221.21%
as of March 31, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-482.06%
as of March 31, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
623.43%
as of March 31, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-2063.80%
as of March 31, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
167.31%
as of Sept. 30, 2025
Industry median 14.05% (173 companies)
Current Ratio
1.67
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.00
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
60.76
as of Sept. 30, 2025
Industry median 10.58 (182 companies)
Net Margin
12.96%
as of Sept. 30, 2025
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
17.32%
as of Sept. 30, 2025
Industry median 14.22% (181 companies)
Operating Margin (TTM)
-1.50%
as of March 31, 2026
Industry median 12.41% (182 companies)
Return on Assets
-3.33%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
-2.00%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
-17.51%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

4 of 6 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.00)
  • No Return on equity is 15% or more (-17.5%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

1 of 2 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

1 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

2 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Undervalued (below its own historical PE range))
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
0.0%
Low 0.2000 · High 0.2200
1W return
-4.5%
Low 0.2000 · High 0.2400
1M return
-12.5%
Low 0.2000 · High 0.2500
52W return
-98.5%
Low 0.1900 · High 0.2500
Lifetime High ₹14.3100 (Dec. 24, 2024)
Lifetime Low ₹0.2000 (Aug. 27, 2026)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
0.2
10D
0.2
20D
0.3
50D
1.3
100D
2.4
200D
3.8

Delivery and volume

Day avg. delivery
44.5%
Week avg. delivery
54.5%
Month avg. delivery
48.8%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

0.21
Pivot
First resistance0.22
Second resistance0.23
Third resistance0.24
First support0.20
Second support0.19
Third support0.18
Day RSI38.9
Day MFI49.3
Day MACD-0.28
Day MACD signal-0.39

Beta

1M2.35
3M1.89
1Y1.89
3Y0.92

Price change analysis

↓ -12.5%
Over 1 Month
LowHigh
0.200.25
↓ -98.5%
Over 3 Months
LowHigh
0.190.25
↓ -98.5%
Over 6 Months
LowHigh
0.190.25
↓ -98.5%
Over 1 Year
LowHigh
0.190.25
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 0.1 (own history: 4.3–5.6)
Undervalued (below its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (March 31, 2026)
₹— Cr
Net profit (March 31, 2026)
₹-50 Cr
Basic EPS (March 31, 2026)
₹-0.4000

Ranks #None of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Dec 2025
  • Public100.00%

Largest holders

Data unavailable.

Historical promoter holding

Historical fii holding

Historical mutual fund holding

All shareholding details →

Deals (Bulk & Block)

All 489 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
23 Apr 2026 KIFS ENTERPRISE Bulk Sell 6,976,552 0.3100 BSE
15 Apr 2026 SATISH KUMAR GRANDHI Bulk Sell 8,290,001 0.3400 BSE
15 Apr 2026 SHARE INDIA SECURITIES LIMITED Bulk Sell 10,852,665 0.3500 BSE
15 Apr 2026 SHARE INDIA SECURITIES LIMITED Bulk Buy 10,852,665 0.3500 BSE
19 Mar 2026 SHARE INDIA SECURITIES LIMITED Bulk Buy 5,925,781 0.2500 BSE
19 Mar 2026 SHARE INDIA SECURITIES LIMITED Bulk Sell 6,624,510 0.2600 BSE
4 Mar 2026 SHARE INDIA SECURITIES LIMITED Bulk Sell 5,096,785 0.3000 BSE
4 Mar 2026 SAROJ KUMAR KUNDU Bulk Buy 5,775,495 0.3000 BSE
4 Mar 2026 TRANSGLOBAL SECURITIES LTD. Bulk Sell 5,866,777 0.3000 BSE
4 Mar 2026 TRANSGLOBAL SECURITIES LTD. Bulk Buy 6,710,361 0.3000 BSE

All bulk and block deals →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.00)
  • Comfortable interest coverage (60.8x)
  • Healthy liquidity (Current Ratio 1.67)
  • Strong revenue growth YoY (167.3%)

Weaknesses

  • Low Return on Equity (-17.5%)
  • Declining profit YoY (-2063.8%)

Opportunities

  • PE below 15 (0.1) relative to a typical growth business

Threats

  • Down 98.5% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Welcure Drugs & Pharmaceuticals ltd

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.